D'anamab: A Phase Three Trial That Slows the Progress of Alzheimer's Disease

D'anamab, not unlike Lekanby, slowed the progress of Alzheimer's disease relative to placebo for patients in the early stages of the disease. We know basically, or we think we know, that the drug works. And based on precedent, both with Lekan by and with Adju-Hom, it seems like Lily has enough to convince the FDA to approve D’anamab.